These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7921515)
1. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Fleishaker JC; Hulst LK; Peters GR Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515 [TBL] [Abstract][Full Text] [Related]
2. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Fleishaker JC; Hulst LK; Peters GR Clin Pharmacol Ther; 1994 Oct; 56(4):389-97. PubMed ID: 7955800 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. Fleishaker JC; Peters GR; Cathcart KS; Steenwyk RC J Clin Pharmacol; 1993 Feb; 33(2):182-90. PubMed ID: 8440768 [TBL] [Abstract][Full Text] [Related]
4. Effect of age and gender on tirilazad pharmacokinetics in humans. Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Fleishaker JC; Peters GR Int J Clin Pharmacol Ther; 1997 Jan; 35(1):28-32. PubMed ID: 9021439 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. Fleishaker JC; Straw RN; Cross CJ J Pharm Sci; 1997 Apr; 86(4):434-7. PubMed ID: 9109044 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. Fleishaker JC; Peters GR; Cathcart KS J Clin Pharmacol; 1993 Feb; 33(2):175-81. PubMed ID: 8382708 [TBL] [Abstract][Full Text] [Related]
8. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Fleishaker JC; Pearson LK; Peters GR Eur J Clin Pharmacol; 1996; 50(1-2):139-45. PubMed ID: 8739825 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304 [TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. Lanzino G; Kassell NF; Dorsch NW; Pasqualin A; Brandt L; Schmiedek P; Truskowski LL; Alves WM J Neurosurg; 1999 Jun; 90(6):1011-7. PubMed ID: 10350245 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Haley EC; Kassell NF; Alves WM; Weir BK; Hansen CA J Neurosurg; 1995 May; 82(5):786-90. PubMed ID: 7714603 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad. Fleishaker JC; Peters GR J Clin Pharmacol; 1996 Sep; 36(9):809-13. PubMed ID: 8889901 [TBL] [Abstract][Full Text] [Related]
13. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). STIPAS Investigators Stroke; 1994 Feb; 25(2):418-23. PubMed ID: 8303754 [TBL] [Abstract][Full Text] [Related]
14. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. Fleishaker JC; Hulst LK; Peters GR J Clin Pharmacol; 1994 Aug; 34(8):837-41. PubMed ID: 7962672 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. Lanzino G; Kassell NF J Neurosurg; 1999 Jun; 90(6):1018-24. PubMed ID: 10350246 [TBL] [Abstract][Full Text] [Related]
16. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. Marshall LF; Maas AI; Marshall SB; Bricolo A; Fearnside M; Iannotti F; Klauber MR; Lagarrigue J; Lobato R; Persson L; Pickard JD; Piek J; Servadei F; Wellis GN; Morris GF; Means ED; Musch B J Neurosurg; 1998 Oct; 89(4):519-25. PubMed ID: 9761043 [TBL] [Abstract][Full Text] [Related]
17. Induction of tirilazad clearance by phenytoin. Fleishaker JC; Pearson LK; Peters GR Biopharm Drug Dispos; 1998 Mar; 19(2):91-6. PubMed ID: 9533108 [TBL] [Abstract][Full Text] [Related]
18. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Peters GR J Pharmacol Exp Ther; 1996 May; 277(2):991-8. PubMed ID: 8627582 [TBL] [Abstract][Full Text] [Related]
19. Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. Smith SL; Scherch HM; Hall ED J Neurosurg; 1996 Feb; 84(2):229-33. PubMed ID: 8592225 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Pearson LK; Fleishaker JC; Peters GR Eur J Clin Pharmacol; 1996; 50(4):299-304. PubMed ID: 8803523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]